@tru.md's peptide therapy claims need fact-checking

What did @tru.md actually say?

The creator responded to a viewer question about BPC-157 injection technique, specifically whether the peptide needs to be injected at a single point or can be spread around an injury site. Their answer: inject subcutaneously near the injury, and the peptide will "get to where it needs to go" on its own. They acknowledged the evidence base is thin, calling their recommendations "all theoretical." Credit where it's due, that caveat matters a lot here.

The framing is practical and clinically cautious, which is more than you get from most peptide content online. But "it makes sense to me" is doing a lot of heavy lifting in a space where mechanism-of-action assumptions have a habit of collapsing under scrutiny.

Does the science back this up?

Partially, but the gaps are significant. BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice, and rodent studies do show interesting systemic effects after subcutaneous injection, including at sites remote from the injection point. Work by Sikiric et al. (2018, Current Pharmaceutical Design) has repeatedly documented what looks like system-wide influence on nitric oxide pathways and growth factor activity. That supports the idea that local injection does not have to be exact.

However, there are no peer-reviewed human pharmacokinetic studies confirming that subcutaneous BPC-157 reliably distributes to specific musculoskeletal injury sites in people. The rodent data is promising, not confirmatory. The claim that the peptide "gets to where it needs to go" implies directed biodistribution that simply has not been demonstrated in humans. The creator said it themselves, theoretical, and that should be the loudest word in this entire video.

What did they get wrong (or right)?

They got the subcutaneous route right. The available animal literature consistently uses subcutaneous or intramuscular administration, not intravenous, and the creator's instruction to inject into "the fat tissue" aligns with that literature. They also correctly implied you do not need to inject directly into a joint or at the exact injury site, which matters because intra-articular self-injection carries real infection and tissue damage risk.

What they got wrong, or at least oversimplified, is the passive distribution claim. Saying BPC-157 "gets to where it needs to go" implies something close to targeted delivery. That is not how subcutaneous peptide absorption works. Absorption is driven by local blood flow, lymphatic drainage, and peptide stability, none of which are injury-specific. A peptide injected near a knee does not preferentially migrate to a torn ACL because the ACL is injured. The injury-site preference idea is an extrapolation from growth factor biology, not a documented property of BPC-157 in humans.

What should you actually know?

BPC-157 remains an investigational compound. It is not FDA-approved for any human indication. All human use currently falls outside regulated clinical trials, which means dosing, injection technique, and safety profiles are not established in the way they are for approved therapeutics. The creator's advice may be reasonable harm reduction for people already using it, but it should not be read as clinical guidance.

The honest summary of the science looks like this:

• Subcutaneous injection is the most studied non-oral route in animals.
• Proximity to an injury site is plausible but unconfirmed as a meaningful variable in humans.
• No human data exists on optimal injection site for musculoskeletal applications.
• The ACL example the creator used is a joint structure with limited direct blood supply, which actually complicates the passive distribution argument further.

If you are considering peptide therapy, that conversation belongs with a licensed provider who can review your specific situation, not a TikTok comment section.